Epizyme, Inc. (NASDAQ:EPZM) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $18.60 and last traded at $18.60, with a volume of 254,057 shares traded. The stock had previously closed at $17.55.

Several analysts have recently weighed in on EPZM shares. BidaskClub upgraded shares of Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. Oppenheimer Holdings, Inc. set a $26.00 price objective on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, June 5th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Tuesday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Epizyme in a research note on Wednesday, June 7th. Finally, Royal Bank Of Canada set a $20.00 price objective on shares of Epizyme and gave the company a “buy” rating in a research note on Monday, June 12th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $23.38.

The firm’s market capitalization is $1.08 billion. The stock’s 50 day moving average is $14.24 and its 200-day moving average is $14.96.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.08. The business had revenue of $10 million during the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm’s quarterly revenue was up 2027.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.49) earnings per share. On average, analysts forecast that Epizyme, Inc. will post ($2.39) earnings per share for the current year.

In other Epizyme news, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction on Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the transaction, the chief financial officer now owns 40,529 shares in the company, valued at $628,199.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $14.87, for a total value of $223,050.00. Following the completion of the transaction, the insider now owns 22,228 shares of the company’s stock, valued at approximately $330,530.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,024 shares of company stock valued at $706,722. 25.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc grew its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. purchased a new stake in shares of Epizyme in the first quarter worth $175,000. BB&T Securities LLC purchased a new stake in shares of Epizyme in the second quarter worth $181,000. Trexquant Investment LP purchased a new stake in shares of Epizyme in the second quarter worth $184,000. Finally, SG Americas Securities LLC grew its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after acquiring an additional 6,072 shares during the last quarter. Institutional investors and hedge funds own 83.74% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Epizyme, Inc. (EPZM) Reaches New 1-Year High at $18.60” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/07/epizyme-inc-epzm-reaches-new-1-year-high-at-18-60.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.